# OnCo record hairy-cell-leukemia (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hairy-cell-leukemia/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hairy-cell-leukemia" ;
  schema:name "Hairy cell leukaemia"@en ;
  schema:description "Hairy cell leukaemia is a rare, slow B-cell leukaemia with a single defining mutation (BRAF V600E) that is unusually curable: one week of a purine analogue puts most people into remission for years, and BRAF drugs rescue those who relapse."@en ;
  schema:url <https://onco.cc/cancers/hairy-cell-leukemia/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hairy_cell_leukemia> ;
  owl:sameAs <http://www.wikidata.org/entity/Q201299> ;
  schema:citation <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1481>, <https://www.hairycellleukemia.org/>, <https://doi.org/10.1056/NEJMoa1014209> ;
  onco:tag "gap-fill", "haematologic" ;
  onco:related <https://onco.cc/cancers/cll/>, <https://onco.cc/cancers/cml/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/monoclonal-antibody/>, <https://onco.cc/technologies/flow-cytometry-mrd/>, <https://onco.cc/technologies/cytotoxic-chemotherapy/> ;
  onco:targets <https://onco.cc/targets/braf/>, <https://onco.cc/targets/cd20/>, <https://onco.cc/targets/cd22/>, <https://onco.cc/targets/cd123/>, <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/moxetumomab-pasudotox/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/interferon-alfa/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/>, <https://onco.cc/companies/astrazeneca/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/mrd/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-tiacci-n-engl-j-med/> ;
  onco:pipeline <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/dabrafenib-trametinib/> ;
  onco:standardOfCare <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/cladribine/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/vemurafenib/>, <https://onco.cc/drugs/rituximab/>, <https://onco.cc/drugs/dabrafenib-trametinib/>, <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/moxetumomab-pasudotox/> .